Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Interest Expenses (2017 - 2024)

Neurocrine Biosciences' Interest Expenses history spans 8 years, with the latest figure at $1.1 million for Q1 2024.

  • For Q1 2024, Interest Expenses changed 0.0% year-over-year to $1.1 million; the TTM value through Dec 2024 reached $1.1 million, down 76.09%, while the annual FY2023 figure was $4.6 million, 35.21% down from the prior year.
  • Interest Expenses reached $1.1 million in Q1 2024 per NBIX's latest filing, roughly flat from $1.1 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $8.5 million in Q3 2020 to a low of $1.1 million in Q4 2022.
  • Average Interest Expenses over 5 years is $4.2 million, with a median of $2.6 million recorded in 2022.
  • Peak YoY movement for Interest Expenses: rose 6.25% in 2020, then crashed 83.33% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $7.8 million in 2020, then decreased by 15.38% to $6.6 million in 2021, then plummeted by 83.33% to $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024.
  • Per Business Quant, the three most recent readings for NBIX's Interest Expenses are $1.1 million (Q1 2024), $1.1 million (Q4 2023), and $1.1 million (Q3 2023).